Zheng Quan Shi Bao Wang·2025-12-07 07:51Core Insights - The National Medical Insurance Drug List for 2025 was officially announced, including the addition of the BTK inhibitor, Ibrutinib (Obinutuzumab), for the first-line treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) patients [1] - Ibrutinib has also successfully renewed its indications for previously treated CLL/SLL, Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL) [1] - The new drug list will be implemented starting January 1, 2026, and was released during the 2025 Innovative Drug High-Quality Development Conference [1] Company Overview - Nocere Biopharma is a commercial-stage biopharmaceutical company focused on developing first-in-class drugs for malignant tumors and autoimmune diseases [3] - The company has multiple new drug products at various stages of commercialization, clinical trials, and preclinical development [3] - Nocere Biopharma has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States [3] Product Details - Ibrutinib, as a result of the national "Major New Drug Creation" initiative, has nearly 100% selectivity for the BTK target, with minimal inter-individual variability and no significant inhibition of other kinases [2] - The drug is administered orally once a day, providing convenience for continuous treatment for patients [2]